Cardiovascular Risk Stratification for Patients Treated With Drug-Eluting Stents: Development and Validation of the...

Area of Science:

• Cardiology
• Interventional Cardiology
• Biostatistics

Background:

• Developing accurate risk prediction models is crucial for managing patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES).
• Major adverse cardiac events (MACE) encompass cardiovascular death, myocardial infarction, and target-lesion revascularization, posing significant risks post-PCI.
• Existing risk stratification tools may not fully capture the complexities of MACE risk in diverse patient populations.

Purpose of the Study:

• To develop and validate a novel risk score for estimating in-hospital and long-term MACE risk following PCI with DES implantation.
• To provide clinicians with a tool for stratifying patients into distinct risk categories (low, moderate, high) for tailored management.
• To improve the prediction of adverse cardiac outcomes across the full spectrum of patient risk profiles.

Main Methods:

• A single-center database of 4061 consecutive patients treated with DES between 2007 and 2014 was utilized.
• The risk score was developed using data from 2863 patients (2007-2012) and validated in 1198 patients (2013-2014).
• Logistic regression and Cox models were employed to develop in-hospital and late follow-up risk scores, respectively, defining MACE as cardiovascular death, myocardial infarction, or ischemia-driven target-lesion revascularization.

Main Results:

• The in-hospital risk score (0-37 points) included factors like age, prior CABG, acute coronary syndrome, peripheral vascular disease, saphenous vein graft treatment, long lesions, small vessels, multivessel disease, and thrombus.
• The late follow-up score (0-45 points) incorporated prior CABG, diabetes mellitus, acute coronary syndrome, multivessel disease, small vessels, ejection fraction <40%, and saphenous vein graft treatment.
• Both scores demonstrated approximately 70% accuracy in predicting MACE and enabled stratification into low-, moderate-, and high-risk groups.

Conclusions:

• A validated risk score has been developed to assess both periprocedural and long-term MACE risk after PCI with DES.
• The score is applicable across a wide range of patient risk profiles and important subgroups.
• This tool supports contemporary risk assessment models for improved patient management post-PCI.